Statin Effects in Atrial Fibrillation-Related Stroke: A Systematic Review and Meta-Analysis

Mi-Yeon Eun¹, Jin-Man Jung²,³*, Kang-Ho Choi⁴ and Woo-Keun Seo⁵*

¹Department of Neurology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea, ²Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, South Korea, ³Korea University Zebrafish Translational Medical Research Center, Ansan, South Korea, ⁴Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea, ⁵Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Background: Statins lower the risk of recurrent stroke and mortality and improve outcomes in patients with ischemic stroke. However, the effects of statins on atrial fibrillation (AF)-related stroke are not well-established. Our study aims to investigate the effects of statin therapy on the clinical outcomes in patients with AF-related stroke.

Methods: Electronic databases (MEDLINE, Embase, and Scopus) were searched for previous studies on the effects of pre- and post-stroke statins on the clinical outcomes in AF-related stroke patients. The primary outcome was all-cause mortality. Secondary outcomes included recurrent ischemic stroke, acute coronary events, major adverse cardiovascular events (MACE), and short-term functional outcomes. We extracted hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (CI) from each study and pooled them through a meta-analysis.

Results: A total of eight studies (five on post-stroke statins and three on pre-stroke statins) with 12,216 patients were included in the analysis. Post-stroke statin therapy reduced the risk of all-cause mortality (HR, 0.63; 95% CI, 0.55–0.74). This beneficial effect was sustained regardless of statin intensity. However, no significant associations were observed between statin therapy and a reduction in the risk of recurrent ischemic stroke, acute coronary events, or MACE. Pre-stroke statin use was associated with a lower risk of poor short-term functional outcomes (OR, 0.63; 95% CI, 0.47–0.85).

Conclusions: Statin therapy for AF-related stroke may reduce all-cause mortality and improve functional outcomes. Randomized controlled studies are warranted to confirm the effects of statins on the outcomes of AF-related stroke.

Keywords: atrial fibrillation, statins, stroke, mortality, functional outcome, systematic review, meta-analysis
INTRODUCTION

Statins or 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors reduce the risk of stroke, cardiovascular events, and mortality in patients with stroke (1, 2), and clinical practice guidelines strongly recommend statin therapy for atherosclerotic cardiovascular diseases and ischemic stroke (3). Statins decrease blood cholesterol and demonstrate pleiotropic effects such as anti-inflammation, endothelial nitric oxide synthase upregulation, and antithrombotic properties (4). Owing to these pleiotropic effects, statins may have broader therapeutic benefits, and they can be effective for non-atherosclerotic diseases. The beneficial effects of statins in treating non-atherosclerotic stroke, such as cancer-related stroke, cardioembolic stroke, and even hemorrhagic stroke, have been reported (5–7).

Atrial fibrillation (AF) is a major cause of ischemic stroke, and the prevalence of AF-related stroke has been increasing with the increase in life expectancy (8, 9). As patients with AF frequently have accompanying atherosclerotic risk factors, prescriptions of statins are also increasing (10, 11). However, the effects of statins in patients with AF-related stroke are not well-established. A major clinical trial, which demonstrated the effects of statins in patients with ischemic stroke, excluded patients with AF (1). Although several observational studies have reported that statins may be beneficial in patients with AF-related stroke, the results are inconclusive (12–14).

In this study, we aimed to investigate and summarize the effects of statin therapy on the clinical outcomes in patients with AF-related stroke through a systematic review and meta-analysis.

METHODS

Search Strategy and Data Sources
We used comprehensive databases (MEDLINE, Embase, and Scopus) to search for previous studies that investigated the effects of pre- and post-stroke statin therapies on the clinical outcomes in patients with AF-related stroke. A literature search was performed by trained medical librarians (Eun Ju Lee and Eun-Ji Kang) from inception up to June 15th, 2020, using the following keywords and MeSH terms in MEDLINE: “atrial-fibrillation,” “stroke,” “statins,” “hydroxymethylglutaryl-CoA reductase inhibitors,” and “outcome.” The search strategy for MEDLINE was developed first, and it was then applied to the other databases. There was no restriction on language. Reference lists of the included articles and literature from manual searches were further screened for additional publications. This meta-analysis was conducted following the PRISMA guidelines (15). It was not registered on an international prospective registration site. This study was also exempt from approval from the Institutional Review Board of our institution because of its design (systematic review and meta-analysis).

Study Selection
The following studies were considered eligible: (1) prospective or retrospective cohort studies or case-control studies; (2) studies that evaluated the effects of pre- or post-stroke statin treatments in patients with ischemic stroke and AF; and (3) studies reporting effect estimates using hazard ratios (HRs) or odds ratios (ORs) with a 95% confidence interval (CI) after statistical adjustment or matching for confounding factors. As we were interested in the effects of statin treatments in AF-related stroke, we excluded reports that evaluated the effects of statins in non-AF cardioembolic stroke. We, however, included one study that involved patients with cardioembolic stroke because it contained AF-related stroke data that could be obtained by contacting the author (6). If two or more studies reported overlapping data, we selected the one that described the time interval between statin therapy and ischemic stroke and data on the outcomes of interest. Two authors (Mi-Yeon Eun and Jin-Man Jung) independently selected the studies for meta-analysis and resolved any disagreements by consensus.

Data Extraction and Assessment of Quality
The extracted data from the studies included the study period, design and setting, demographic findings, prescription rate of statins and anticoagulants, and hazard or odds ratios with 95% confidence interval for the clinical outcomes of interest. If necessary, we contacted the authors to obtain additional unpublished data. Quality assessments were performed using the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS) (16). RoBANS comprises six components (selection of participants, confounding variables, measurement of intervention, blinding for outcome assessment, incomplete outcome data, and selective outcome reporting). A high, low, or unclear risk was assigned to each item using the assessment criteria. Data extraction and assessment of quality were performed independently by two authors (Mi-Yeon Eun and Jin-Man Jung), and any disagreements were resolved by discussion.

Outcomes of Interest
The primary outcome of this study was all-cause mortality. We thought that it was appropriate to prove the pleiotropic effects of statins. Secondary outcomes included recurrent ischemic stroke, acute coronary events, major adverse cardiovascular events (MACE), and short-term poor functional outcomes. Acute coronary events included acute coronary syndrome and myocardial infarction according to the definitions used by the included studies. The MACE was defined following the definitions used in the included studies; such definitions are heterogeneous. A poor functional outcome was defined as mRS 4–6 or mRS 3–6 (from 1 month to 3 months after discharge) depending on the studies.

Statistical Analysis
The meta-analysis in this study was performed using the outcomes reported by at least two of the included studies. We obtained the pooled effect sizes using the DerSimonian and Laird methods with the random-effects model. The meta-analyses of specific outcomes were pooled using HRs with 95% CI for post-stroke statin therapy and ORs with 95% CI for pre-stroke statin therapy from each study. We applied the Cochran Q test and $I^2$ statistics to estimate heterogeneity. An $I^2$ value of <25% was considered low, >25% but <75% was considered moderate, and...
>75% was considered significant (17). Subgroup analyses of all-cause mortality and recurrent ischemic stroke were performed according to statin intensity (high and low-to-moderate) and the types of included patients (hospital-based and population-based). Sensitivity analyses were performed by sequential removal of an individual study to assess whether it influenced the overall results. Publication bias tests using funnel plot and Egger’s test were conducted in cases where the included studies were at least ≥10. We used the RevMan software version 5.3 for these analyses.

**RESULTS**

**Study Characteristics**

A total of 1,742 studies were obtained from the search. After removing duplicates and screening by title and abstract, we manually reviewed 32 full-text articles. Twenty-four articles were excluded for (1) not comparing statin users and non-users; (2) not reporting adjusted effect estimates; (3) not providing data about the outcomes of interest; and (4) having overlapping study populations. Finally, eight studies (five studies for post-stroke statin; three studies for pre-stroke statin) were included in this meta-analysis (Figure 1) (6, 12–14, 18–21). We excluded the study of Lin et al. (22) because of the population overlap with the study of Wu et al. (13) and the lack of information on the initiation time of statin treatment after AF-related stroke. The characteristics of the included studies are demonstrated in Table 1. The prevalence of paroxysmal AF ranged from 24.3 to 54.9% of the study population. The proportion of patients using post-stroke statin therapy in individual studies ranged from 25.2 to 73.3%. The percentage of patients managed with anticoagulants ranged from 23.6 to 71.3%. The longest median follow-up was 2.4 years. All of these publications were observational studies, and they included 12,216 subjects. Six studies were performed using a single-center or multicenter hospital-based registry on acute ischemic stroke (6, 12, 14, 19–21). The other two studies were population-based (13, 18). The adjusted hazard or odds ratios were obtained from these studies. The common adjusted variables for the effect of post-stroke statin on mortality in hospital-based studies were age, sex, hypertension, diabetes mellitus, and stroke severity assessed by the National Institute of Health Stroke Scale (NIHSS). Hayden et al. (18) conducted a population-based cohort study, which adjusted pre-stroke functional status, type of AF, and CHADS2 score for assessing the effect of statins on mortality (18). A study by Wu et al. (13) identified subjects using the Taiwan National Health Insurance Research Database. This study included patients receiving statins after recent ischemic stroke and matched controls in a 1:2 ratio.
### TABLE 1 | Characteristics of included studies.

| Author      | Study period | Design/setting | No  | Baseline features | Outcome                  | Follow-up (IQR) |
|-------------|--------------|----------------|-----|-------------------|--------------------------|-----------------|
| Ntaios G*   | 2000–2011    | (Retrospective/11 centers) | 404 | Age (SD) 67.2 (12.3) | Male 68.2, HTN 76.0, Hyperlipidemia 33.7, Statin 25.2, OAC 71.3 | Mortality, Recurrent IS, MACE† | 22 mon (9–48) |
| Choi JY*    | 2008–2012    | Retrospective/3 centers | 376 | Age (SD) 71.2 (10.9) | Male 52.4, HTN 69.2, Hyperlipidemia N/A, Statin 45.5, OAC 64.6 | Mortality, Recurrent IS, Mortality | None, None | 17.4 mon (9.0–34.1) |
| Hayden DT†  | 2005–2006    | Prospective/Population-based cohort | 160 | Age (SD) N/A | Male N/A, HTN N/A, Hyperlipidemia N/A, Statin 72.7, OAC 36.5 | Mortality | None | N/A |
| Choi KH†    | 2013–2015    | Prospective/11 centers | 2,153 | Age (SD) 73.2 (9.8) | Male 52.0, HTN 69.9, Hyperlipidemia 23.3, Statin 73.3, OAC 62.5 | MACE‡, Components of MACE‡ | 17.3 mon (4.3–31.3) |
| Wu YL*      | 2000–2011    | Retrospective/Multicenter | 4,638 | Age (SD) 75.6 (7.4) | Male 49.1, HTN 96.6, Hyperlipidemia N/A, Statin 33.3, OAC 39.7 | Recurrent stroke | 2.4 years (1.3–4.1) |
| Ko D†       | 2000–2011    | Retrospective/3 centers | 1,030 | Age (SD) 77.0 (11.1) | Male 44.1, HTN 90.7, Hyperlipidemia N/A, Statin 38.8 (pre-), OAC 28.4 | Poor functional outcome (mRS 4–6), Mortality | None | 30 days |
| He L†       | 2015–2018    | Prospective/4 centers | 242 | Age (SD) N/A | Male 48.8, HTN 69.8, Hyperlipidemia 49.2, Statin 43.8 (pre-), OAC 23.6 | Mortality, Poor functional outcome (mRS 3–6) | Composite of mortality/major disability | 3 mon |
| Song TJ†    | 2013–2015    | Prospective/11 centers | 3,213 | Age (SD) 73.4 (9.6) | Male 50.7, HTN 68.7, Hyperlipidemia 18.6, Statin 20.2 (pre-), OAC 53.7 | Poor functional outcome (mRS 3–6) | None | 3 mon |

SD, standard deviation; IQR, interquartile range; OAC, oral anticoagulation; N/A, not applicable; IS, ischemic stroke; MACE, major adverse cardiovascular events; mon, months; MI, myocardial infarction; mRS, modified Rankin Scale; HTN, hypertension.

*Post-stroke statin study.
†Pre-stroke statin study.
‡MACE† was defined as stroke recurrence, myocardial infarction, aneurysm rupture, and sudden cardiac death.
§MACE‡ was defined as death from any cause, non-fatal stroke, acute coronary syndrome, and major hemorrhage.
∥MACE§ was defined as any ischemic or hemorrhagic stroke, and myocardial infarction.
Based on age, sex, cardiovascular risk factors, and the estimated NIHSS score.

Quality of the Included Studies
Potential sources of bias in the included studies are presented in Supplementary Figure 1. The likelihood of selection bias was generally low except for some studies on pre-stroke statin effects (20, 21). As we included studies that reported estimates after adjusting for or matching confounding factors, the risk of confounding was also low. Blinding was not applied to the outcome assessments in any of the included studies. However, mortality was considered unaffected by blinding. Reporting bias was unclear in most of these publications.

Effect of Post-stroke Statin Therapy on Clinical Outcomes
The number of included studies in the meta-analyses on all-cause mortality, recurrent ischemic stroke, acute coronary events, and MACE were 5, 4, 2, and 3, respectively (Figure 2). Post-stroke statin therapy was associated with a reduced risk of all-cause mortality (HR, 0.63; 95% CI, 0.55–0.74) with a low heterogeneity ($I^2 = 14\%$). The effect of statins on mortality was maintained even after adjustment for the type of AF (HR, 0.53; 95% CI, 0.34–0.84) in a study by Hayden et al. (18). In contrast, post-stroke statins were not effective in preventing recurrent ischemic stroke (HR, 0.88; 95% CI, 0.64–1.21) and acute coronary events (HR, 1.22; 95% CI, 0.82–1.82). The results for recurrent ischemic stroke showed moderate heterogeneity between the studies ($I^2 = 52\%$). On the other hand, low heterogeneity ($I^2 = 0\%$) was found for acute coronary events. Regarding MACE, post-stroke statin therapy was not associated with a decreased risk of events (HR, 0.72; 95% CI, 0.47–1.11) with high heterogeneity ($I^2 = 90\%$).

Subgroup Analyses of Post-stroke Statin Therapy Studies
We conducted subgroup analyses to assess the effects of post-stroke statin therapy on clinical outcomes stratified by statin intensity and patient subgroup type (hospital-based vs. population-based). Two studies analyzed the intensity-related effects of statin therapy on mortality and recurrent ischemic stroke (6, 14). In terms of all-cause mortality, a meta-analysis of the high-intensity vs. no statin and the high-intensity vs. low-to-moderate-intensity statin groups could not be conducted because no deaths occurred in the high-intensity group in one study (6) during the follow-up period (Figures 3A,C). In the other report, the risk of all-cause mortality was lower with high-intensity statin therapy than without statin therapy (HR, 0.47; 95% CI, 0.35–0.63), and it was more effective than the low-to-intermediate intensity statin treatments (HR, 0.70; 95% CI, 0.53–0.92) (14). The risk of all-cause mortality was also lower with low-to-moderate intensity statin therapy in our meta-analysis than without statin therapy with moderate heterogeneity (HR, 0.53; 95% CI, 0.30–0.94) (Figure 3B). The prevention of recurrent ischemic stroke by statin therapy was not effective irrespective of the intensity (Figures 3D,E). However, high-intensity statin therapies marginally decreased the risk of recurrent ischemic stroke (HR, 0.68; 95% CI, 0.44–1.04) (Figure 3D). High-intensity statin therapy was not more effective in lowering the risk of recurrent ischemic stroke than low-to-moderate intensity statin therapy (Figure 3F).

The subgroup analyses showed that post-stroke statin therapy was associated with a reduced risk of mortality in the hospital-based (OR, 0.58; 95% CI, 0.48–0.70) and population-based studies (OR 0.67; 95% CI 0.49–0.90) with low heterogeneity. However, the post-stroke statin therapy had no benefit for the prevention of recurrent ischemic stroke in subgroup analyses, and these results were consistent with the primary meta-analysis. Regarding MACE, studies using a hospital-based registry demonstrated favorable results in post-stroke statin users (OR, 0.62; 95% CI, 0.48–0.79); this result was not seen in the population-based studies (OR 1.03; 95% CI, 0.90–1.18). The outcomes of the subgroup analyses, stratified by the patient subgroup type, are shown in Supplementary Figure 2.

Sensitivity Analysis and Publication Bias
We conducted a sensitivity analysis of post-stroke statin effects on all-cause mortality. It demonstrated that the exclusion of any individual study did not significantly influence the effect of post-stroke statin therapy (Supplementary Figure 3). We did not use Egger’s test and the funnel plot; we planned to use them if at least ten studies were included in the meta-analysis.

Effect of Pre-stroke Statin Therapy on Clinical Outcomes
Three studies were used in our meta-analysis for poor functional outcomes (19–21). Pre-stroke statin therapy was associated with a reduced risk of poor functional outcomes (OR, 0.63; 95% CI, 0.47–0.85) with moderate heterogeneity ($I^2 = 33\%$) (Figure 2E). Among the included studies, only the study by He et al. (19) adjusted the type of AF. Although a meta-analysis was not conducted, the study by He et al. (19) showed that pre-stroke statin was inversely associated with the 3-month mortality (OR, 0.38; 95% CI, 0.16–0.91). We did not perform subgroup and sensitivity analyses owing to the limited number of studies included.

DISCUSSION
With data of 12,216 patients from eight studies, this meta-analysis demonstrates the beneficial effect of pre- and post-stroke statin therapy in patients with AF-related stroke. Specifically, post-stroke statin therapy was associated with a 36% reduced risk of all-cause mortality. The result was consistent across the included studies with low heterogeneity. In addition, it was irrespective of statin intensity and patient subgroup type. Although a meta-analysis was not performed, high-intensity statin therapy seemed to be associated with a lower risk of all-cause mortality than low-to-moderate-intensity statin therapy (14). However, post-stroke statin therapy in those studies did not prevent recurrent ischemic stroke, acute coronary events, and MACE. On the other hand, pre-stroke statin therapy was associated with a lower risk of short-term poor functional outcomes.

Several studies have reported that statin therapy is beneficial in patients with stroke. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial reduced the incidence of strokes and cardiovascular events. However,
A  All-cause mortality

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|-----|--------|---------------------------------|--------------------------------|
| Choi JY 2014      | -0.7981          | 0.3794 | 4.0%   | 0.45 [0.21, 0.95]              |                                |
| Choi KH 2019      | -0.5062          | 0.1062 | 38.0%  | 0.60 [0.49, 0.74]              |                                |
| Hayden DT 2015    | -0.6266          | 0.2307 | 10.3%  | 0.53 [0.34, 0.84]              |                                |
| Ntaios G 2014     | -0.7162          | 0.2224 | 5.5%   | 0.49 [0.26, 0.92]              |                                |
| Wu YL 2017        | -0.3011          | 0.0986 | 42.2%  | 0.74 [0.61, 0.90]              |                                |
| Total (95% CI)    | 100.0%           | 0.63 [0.55, 0.74] |                        |                                |
| Heterogeneity:    | Tau² = 0.00; Chi² = 4.64, df = 4 (P = 0.33); I² = 14% |                          |                                |

Test for overall effect: Z = 5.89 (P < 0.00001)

B  Recurrent ischemic stroke

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|-----|--------|---------------------------------|--------------------------------|
| Choi JY 2014      | 0.3001           | 0.431 | 11.1%  | 1.35 [0.68, 2.24]              |                                |
| Choi KH 2019      | -0.2614          | 0.2003 | 28.9%  | 0.77 [0.52, 1.14]              |                                |
| Ntaios G 2014     | -0.7551          | 0.3873 | 13.3%  | 0.47 [0.22, 1.00]              |                                |
| Wu YL 2017        | 0.0392           | 0.0738 | 47.0%  | 1.04 [0.90, 1.20]              |                                |
| Total (95% CI)    | 100.0%           | 0.88 [0.64, 1.21] |                        |                                |
| Heterogeneity:    | Tau² = 0.02; Chi² = 6.24, df = 3 (P = 0.10); I² = 52% |                          |                                |

Test for overall effect: Z = 0.76 (P = 0.45)

C  Acute coronary events

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|-----|--------|---------------------------------|--------------------------------|
| Wu YL 2017        | 0.2073           | 0.2131 | 91.0%  | 1.23 [0.81, 1.87]              |                                |
| Choi KH 2019      | 0.1243           | 0.676 | 9.0%   | 1.13 [0.30, 4.26]              |                                |
| Total (95% CI)    | 100.0%           | 1.22 [0.82, 1.82] |                        |                                |
| Heterogeneity:    | Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0% |                          |                                |

Test for overall effect: Z = 0.90 (P = 0.33)

D  MACE

| Study or Subgroup | log[Hazard Ratio] | SE  | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|-----|--------|---------------------------------|--------------------------------|
| Choi KH 2019      | -0.4358          | 0.093 | 38.4%  | 0.65 [0.54, 0.78]              |                                |
| Ntaios G 2014     | -0.6212          | 0.3537 | 19.3%  | 0.44 [0.22, 0.88]              |                                |
| Wu YL 2017        | 0.0296           | 0.0868 | 40.7%  | 1.03 [0.99, 1.12]              |                                |
| Total (95% CI)    | 100.0%           | 0.72 [0.47, 1.11] |                        |                                |
| Heterogeneity:    | Tau² = 0.11; Chi² = 19.88, df = 2 (P < 0.0001); I² = 90% |                          |                                |

Test for overall effect: Z = 1.49 (P = 0.14)

E  Poor functional outcome – Pre-stroke statin therapy

| Study or Subgroup | log[Odds Ratio] | SE  | Weight | Odds Ratio IV, Random, 95% CI | Odds Ratio IV, Random, 95% CI |
|-------------------|-----------------|-----|--------|-------------------------------|-------------------------------|
| He L 2019         | -1.1712         | 0.4439 | 10.3%  | 0.31 [0.13, 0.74]              |                                |
| Ko D 2017         | -0.3657         | 0.1569 | 47.5%  | 0.66 [0.50, 0.92]              |                                |
| Song TJ 2019      | -0.3711         | 0.1746 | 42.3%  | 0.69 [0.49, 0.97]              |                                |
| Total (95% CI)    | 100.0%           | 0.63 [0.47, 0.85] |                        |                                |
| Heterogeneity:    | Tau² = 0.02; Chi² = 2.98, df = 2 (P = 0.23); I² = 33% |                          |                                |

Test for overall effect: Z = 3.07 (P = 0.002)

FIGURE 2 | Meta-analyses on the effect of post-stroke statin therapy on (A) all-cause mortality, (B) recurrent ischemic stroke, (C) acute coronary events, (D) MACE, and meta-analysis on the effects of pre-stroke statin therapy on (E) poor functional outcomes in patients with atrial fibrillation-related stroke. MACE, major adverse cardiovascular events.
FIGURE 3 | Subgroup meta-analyses on the effect of post-statin therapy on (A) all-cause mortality (high-intensity statin vs no statin), (B) all-cause mortality (low-to-intermediate-intensity statin vs no statin), (C) all-cause mortality (high-intensity vs low-to-moderate intensity statin), (D) recurrent ischemic stroke (high-intensity statin vs no statin), (E) recurrent ischemic stroke (low-to-intermediate-intensity statin vs no statin), and (F) recurrent ischemic stroke (high-intensity vs low-to-moderate-intensity statin) stratified by the intensity of statins.
that statin therapy also contributed to reduced mortality and ejection fraction (hospitalization in patients with heart failure with preserved ejection fraction). AF shares risk factors with atherosclerosis, which include old age, hypertension, and diabetes mellitus. As statins have anti-atherogenic and antithrombotic effects, they may reduce the risk of vascular events and cardiovascular mortality in AF-related stroke. However, in this meta-analysis, statin therapy did not reduce the vascular events, including recurrent ischemic stroke, acute coronary events, and MACE. Recent cohort studies involving older adult participants without atherosclerotic cardiovascular disease have reported that statin treatment has a major advantage for mortality over prevention of ischemic stroke or myocardial infarction.

The mechanism by which statins reduce stroke-related mortality is uncertain. Several biomarkers of stroke indicate that various mechanisms underlie stroke occurrence and prognosis. We speculated that the systemic pleiotropic effects of statins, including an anti-inflammatory effect, anti-oxidant effect, improvement in endothelial function, and angiogenesis, may contribute to reduced mortality. Additionally, post-stroke statins were associated with good functional outcomes in patients with stroke because of the neuroprotective effects. Since good functional outcomes after stroke were independently predictive of survival, statins may have favorable effects on mortality. Finally, statins have potential benefits for heart disorders, which are major causes of mortality in patients with ischemic stroke. Anti-inflammatory and anti-oxidant effects of statins may result in an anti-arrhythmic potential and reduce the burden of AF, and statins have been reported to prevent the recurrence of AF, especially in patients with coronary artery disease. Besides, a recent cohort study demonstrated that statin therapy also contributed to reduced mortality and hospitalization in patients with heart failure with preserved ejection fraction.

Although a meta-analysis was not performed, high-intensity statins seemed to be more effective in reducing all-cause mortality than low-to-moderate-intensity statins in one of the included studies. Previous studies involving patients with acute ischemic stroke or atherosclerotic cardiovascular disease demonstrated an association between the intensity of statin therapy and mortality. However, there was insufficient evidence to confirm this hypothesis because there were only a few relevant studies on AF-related stroke.

In our meta-analysis, post-stroke statin therapy was not effective in preventing recurrent ischemic stroke in patients with AF-related stroke. Anticoagulation is the main treatment for prevention of stroke or systemic embolization due to AF. Although statins are presumed to have antithrombotic effects, these effects may not be sufficient to prevent recurrent ischemic stroke caused by AF. These results were consistent with the results of a recent observational study involving patients with cardioembolic stroke that indicated that post-stroke statin therapy was associated with a reduced risk of mortality but not associated with the risk of recurrent stroke.

However, post-stroke statins can lower the risk of ischemic stroke of atherosclerotic origin. In a study by Ntaios et al., post-stroke statins appeared to decrease the risk of recurrent stroke. Patients included in this study had relatively frequent hypertension (76.0%) and low high-density lipoprotein cholesterol levels ([statin user, 133.1 mg/dl (47.7); non-statin user, 117.5 mg/dl (37.0)] in post-stroke statin studies. Besides, the proportion of patients receiving anticoagulation was the highest (71.3%). The effect size of statins in preventing atherosclerotic vascular events may vary depending on the risk factors. Furthermore, these effects can be prominent in patients undergoing anticoagulation. Thus, baseline characteristics and anticoagulation status should be considered to interpret the effects of statin therapy in AF-related stroke.

Statin therapy was also not effective for the prevention of MACE. However, there was significant heterogeneity among the studies because of the varying definitions of MACE. In two studies that included mortality in the definition of MACE, post-stroke statin therapy was effective in reducing MACE. These findings also supported the possible beneficial effects of statins on the mortality observed in our study.

In our meta-analysis, pre-stroke statin therapy was related to the reduced risk of short-term poor functional outcomes in AF-related stroke. These results were consistent with reports from previous studies that indicated pre-stroke statins to be associated with milder stroke and improved functional outcomes. Statins can help reverse endothelial dysfunction, augmentation in the nitric oxide-mediated vasodilation, or plaque stabilization. Furthermore, they were reported to increase the collateral blood flow in AF-related stroke, leading to a lower infarct core and more efficient recoveries. Thus, pre-stroke statins were presumed to be neuroprotective against AF-related as well as atherosclerotic stroke.

Several limitations should be noted. First, we were unable to exclude the possibility of undetected confounding and selection bias because all of our included reports were non-randomized observational studies. Most of the included studies also had a retrospective design. Second, the baseline characteristics and the definitions of the outcomes in the included studies were heterogeneous. Thus, some results of these meta-analyses also had moderate to high statistical heterogeneity. Third, the effects of pre-stroke and post-stroke statin therapies overlap and do not occur in isolation. Most patients treated with pre-stroke statin therapy continued statin therapy after stroke. A considerable number of patients receiving post-stroke statin therapy also received pre-stroke statin therapy. Finally, our meta-analysis was not an individual patient-level pooled analysis, and therefore, we could not fully evaluate the statin type, dosage, adherence, the oral anticoagulant type at discharge, the subtype of AF such as paroxysmal vs. sustained, valvular vs. non-valvular, and the co-existence of a mechanical heart valve.
Despite these limitations, our meta-analysis has some strengths. First, we focused on the effects of statins in patients with AF-related, and not cardioembolic, stroke. Since cardioembolic stroke is attributable to heterogeneous patients with AF-related, and not cardioembolic, stroke.

CONCLUSIONS

Statin therapy is associated with a reduced risk of all-cause mortality, and pre-stroke statins can improve functional outcomes in AF-related stroke. Given the limitations of this study, especially related to the observational studies included, well-designed randomized controlled studies are required to confirm the effects of statins on the clinical outcomes of AF-related stroke.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/Supplementary Material.

REFERENCES

1. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. (2006) 355:549–59. doi: 10.1056/NEJMoa061894
2. Hong KS, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke. (2015) 17:282–301. doi: 10.5853/jos.2015.17.3.282
3. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACP/AANS/AGS/APhA/ASPAC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. (2019) 139:e1082–143. doi: 10.1161/CIR.0000000000006699
4. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. (2017) 120:229–43. doi: 10.1161/CIRCRESAHA.116.308537
5. Kim YS, Park MS, Lee H, Chung JW, Lee MJ, Kim CK, et al. Effect of statins on survival following stroke in patients with cancer. Front Neurol. (2018) 9:205. doi: 10.3389/fneur.2018.00205
6. Choi JY, Seo WK, Kang SH, Jung JM, Cho KH, Yu S, et al. Statins improve survival in patients with cardioembolic stroke. Stroke. (2014) 45:1849–52. doi: 10.1161/STROKEAHA.114.005518
7. Jung JM, Choi JY, Kim HJ, Seo WK. Statin use in spontaneous intracerebral hemorrhage: a systematic review and meta-analysis. Int J Stroke. (2015) 10(Suppl. A) 100:10–7. doi: 10.1111/ijs.12624
8. Otite FO, Khandelwal P, Chaturvedi S, Romano JG, Sacco RL, Malik AM. Increasing atrial fibrillation prevalence in acute ischemic stroke and TIA. Neurology. (2016) 87:2034–42. doi: 10.1212/WN1.000000000003321
9. Kim JY, Kang K, Kang J, Koo J, Kim DH, Kim BJ, et al. Executive summary of stroke statistics in Korea 2018: a report from the epidemiology research council of the Korean stroke society. J Stroke. (2019) 21:42–59. doi: 10.5853/jos.2018.03125
10. Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. NCHS Data Brief. (2014) 171:1–8.
11. Korean Society of Lipidology and Atherosclerosis. Dyslipidemia Fact Sheets in Korea. (2018). Available online at: http://www.lipid.or.kr/file/Dyslipidemia%20Fact%20Sheets%20in%20Korea%202018.pdf (accessed June 20, 2019).
12. Ntaios G, Papavasileiou V, Makaritsis K, Millionis H, Manios E, Michel P, et al. Statin treatment is associated with improved prognosis in patients with AF-related stroke. Int J Cardiol. (2014) 177:129–33. doi: 10.1016/j.ijcard.2014.09.031
13. Wu YL, Saver JL, Chen PC, Lee JD, Wang HH, Rao NM, et al. Effect of statin use on clinical outcomes in ischemic stroke patients with atrial fibrillation. Medicine. (2017) 96:e5918. doi: 10.1097/MD.000000000005918
14. Choi KH, Seo WK, Park MS, Kim JT, Chung JW, Bang OY, et al. Effect of statin therapy on outcomes of patients with acute ischemic stroke and atrial fibrillation. J Am Heart Assoc. (2019) 8:e013941. doi: 10.1161/JAHA.119.013941

AUTHOR CONTRIBUTIONS

M-YE searched for studies, screened references, extracted data, assessed risk of bias, performed the analyses, and drafted the manuscript. J-MJ conceived the study, searched for studies, screened references, collected data, assessed risk of bias, performed the analyses, drafted, and critically revised the manuscript. K-HC contributed to data collection and critically revised the manuscript. W-KS contributed to data collection and edited and critically revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Research Foundation of Korea funded by the Ministry of Education (2019R1A2C2008788) and a Korea University grant. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or publishing of the results.

ACKNOWLEDGMENTS

The authors thank Eun Ju Lee and Eun-Ji Kang from the Medical Library, Korea University, for searching abstracts and articles related to this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.589684/full#supplementary-material.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *BMJ* (2009) 339:b2535. doi:10.1136/bmj.b2535

16. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. *J Clin Epidemiol*. (2013) 66:408–14. doi:10.1016/j.jclinepi.2012.09.016

17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi:10.1136/bmj.327.7414.557

18. Hayden DT, Hannon N, Callaly E, Ni Chrónín D, Horgan G, Kyne L, et al. Rates and determinants of 5-year outcomes after atrial fibrillation-related stroke: a population study. *Stroke*. (2015) 46:3488–93. doi:10.1161/STROKEAHA.115.011139

19. He L, Xu R, Wang J, Zhang L, Zhang L, Zhao W, et al. Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke. *BMRC Neurol*. (2019) 19:240. doi:10.1186/s12883-019-1463-7

20. Ko D, Thigpen JL, Otis JA, Forster K, Renault L, Quinn E, et al. Influence of statin therapy at the time of stroke onset on functional outcome among patients with atrial fibrillation. *Int J Cardiol*. (2017) 227:808–12. doi:10.1016/j.ijcard.2016.10.055

21. Song TJ, Baek IY, Woo HG, Kim YJ, Chang Y, Kim BJ, et al. Characteristics and factors for short-term functional outcome in stroke patients with atrial fibrillation, nationwide retrospective cohort study. *Front Neurol*. (2019) 10:1101. doi:10.3389/fneur.2019.01101

22. Lin HC, Tsai WC, Lin JR, Chang WN, Huang CC, Wang HC, et al. Adjunctive statin therapy reduces intracranial hemorrhage and 1-year mortality in patients with atrial fibrillation after acute ischemic stroke: a population-based epidemiological study from Taiwan. *J Clin Neurosci*. (2019) 69:224–29. doi:10.1016/j.jocn.2019.07.045

23. Ni Chrónín D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin population stroke study. *Stroke*. (2011) 42:1021–29. doi:10.1161/STROKEAHA.110.596734

24. Miloritis HJ, Giannopoulos S, Kosmidou M, Panoulas V, Maniotes E, Kyritsis AP, et al. Statin therapy after the first stroke reduces 10-year stroke recurrence and improves survival. *Neurology*. (2009) 72:1816–22. doi:10.1212/WNL.0b013e3181a771cb

25. Miller JD, Aronis KN, Chrispin J, Patil KD, Marine JE, Martin SS, et al. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. *J Am Coll Cardiol*. (2015) 66:2899–906. doi:10.1016/j.jacc.2015.10.047

26. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. *Eur Heart J*. (2002) 23:1908–21. doi:10.1053/ehj.2002.3256

27. Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. *JAMA*. (2020) 324:68–78. doi:10.1001/jama.2020.7848

28. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. *J Neuroendocrinol*. (2013) 25:771–8. doi:10.1111/jne.12053

29. Kim SJ, Moon GJ, Bang OY. Biomarkers for stroke. *Stroke*. (2015) 15:27–37. doi:10.5883/jos.2013.15.1.27

30. Kureishi Y, Luo Z, Shiogoma I, Bialak A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. *Nat Med*. (2000) 6:1004–10. doi:10.1038/79510

31. Delanty N, Vaughan CJ, Sheehy N. Statins and neuroprotection. *Expert Opin Investig Drugs*. (2001) 10:1847–53. doi:10.1517/13543784.10.1847

32. Eriksson M, Norrving B, Terent A, Stegmayr B. Functional outcome 3 months after stroke predicts long-term survival. *Cerebrovasc Dis*. (2008) 25:423–29. doi:10.1159/000121143

33. Savelieva I, Cannm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. *Nat Clin Pract Cardiovasc Med*. (2008) 5:30–41. doi:10.1038/ncp10183

34. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. *Br J Clin Pharmacol*. (2012) 74:74–76. doi:10.1111/j.1365-2125.2012.04258.x

35. Lee MS, Duan L, Clare R, Hekimian A, Spencer H, Chen W. Comparison of effects of statin use on mortality in patients with heart failure and preserved versus reduced left ventricular ejection fraction. *Am J Cardiol*. (2018) 122:405–12. doi:10.1016/j.amjcard.2018.04.027

36. Kim J, Lee HS, Nam CM, Hoo JH. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. *Stroke*. (2017) 48:2723–30. doi:10.1161/STROKEAHA.117.018140

37. Rodríguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol*. (2017) 2:47–54. doi:10.1001/jamacardio.2016.4052

38. Park HK, Lee JS, Hong KS, Cho YJ, Park JM, Kang K, et al. Statin therapy in acute cardioembolic stroke with no guidance-based indication. *Neurology*. (2020) 94:e1984–95. doi:10.1212/WNL.0000000000009937

39. Paciarioni M, Agnelli G, Ageno W, Caso V, Corea F, Lanari A, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. *Atherosclerosis*. (2010) 212:564–66. doi:10.1016/j.atherosclerosis.2010.06.016

40. Greisenegger S, Müllner M, Tentscher S, Lang W, Lalouchsek W. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. *J Neurol Sci*. (2004) 221:5–10. doi:10.1016/j.jns.2004.01.015

41. Martí-Fàbregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. *Stroke*. (2004) 35:1117–21. doi:10.1161/01.STR.0000125863.93921.3F

42. Lee MJ, Bang OY, Kim SJ, Kim GM, Chung CS, Lee KH, et al. Role of statin in atrial fibrillation-related stroke: an angiographic study for collateral flow. *Cerebrovasc Dis*. (2014) 37:77–84. doi:10.1159/000356114

Conflict of Interest: J-MJ has received lecture honoraria from Pfizer, Sanofi-Aventis, Otsuka, Dong-A, Hanmi Pharmaceutical Co., Ltd., and Boryung Pharmaceutical Co., Ltd.; consulting fees from OBELAB Inc and Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Korea Co., Ltd., and Boryung Pharmaceutical Co., Ltd., Daiichi Sankyo Korea Co., Ltd., and Boryung Pharmaceutical Co., Ltd.; consulting fees from OBELAB Inc.

The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as potential conflicts of interest.

Copyright © 2020 Eun, Jung, Choi and Seo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.